Sector dossier

Health care sector detail

Health care is where dependence is total, information is weakest, and institutions can deny responsibility while still deciding whether people get treated in time.

Why ripe

Why health care is a life industry

Patients cannot shop normally in emergencies or during serious illness.
Price, quality, and necessity are all hard to evaluate in real time.
Providers, hospitals, drug firms, and insurers each pass costs and blame across the chain.
Failure means pain, disability, or death, not just inconvenience.

Deregulation arc

How leakiness emerges

1. Market language enters care
Care is framed as a competitive service market rather than a public system.

2. Intermediaries thicken
Billing networks, formularies, provider groups, and private administrators multiply.

3. Costs become opaque
Patients cannot know the actual price or incentive structure before treatment.

4. Harm gets individualized
Systemic denial, delay, and under-service appear as paperwork, authorization, or isolated provider failure.

U.S. pattern

Fragmented care, strong extraction

The U.S. health system is a layered public-private hybrid with broad insurance coverage expansions but still no unified cost discipline across hospitals, physicians, drug firms, and payers.

Access is mediated by network rules, plan design, and reimbursement incentives.
Drug spending and treatment costs create persistent conflict between access and affordability.
Price opacity makes patient choice weak as a disciplining force.
Care can be rationed by billing complexity, administrative burden, and delay rather than openly by law.

China pattern

Integrated reform, stronger state steering

China has pushed “triple-medical” reform to coordinate hospitals, pharmaceuticals, and health insurance under a stronger public framework.

Public insurance coverage expanded to most of the population through large state schemes.
Volume-based drug procurement and payment reform are used to cut prices and align incentives.
The state has more direct leverage over provider behavior and pharmaceutical pricing than the U.S.
But tradeoffs remain around quality, hospital incentives, and balancing cost control with innovation.

Comparison

U.S. vs China health care

Dimension	United States	China
System form	Fragmented mixed public-private coverage	Broad state-backed insurance with stronger central coordination
Main leak	Administrative opacity, price fragmentation, access by paperwork	Cost-control pressure, uneven quality, hospital-pharma incentive tensions
Policy style	Incremental reform inside a commercial architecture	Top-down coordination across insurance, pharma, and provider systems
Public danger	Treatment delayed or denied through complexity and cost	Care standardized and cheaper, but still shaped by institutional and regional disparities

What to research

Health-care dossier prompts

Where exactly does denial happen: provider shortage, billing friction, prior authorization, or drug price?
Which actors can profit while disclaiming responsibility for outcomes?
How do cost controls differ from care rationing in each system?
What structural reforms would turn treatment access into a public guarantee instead of a negotiated commodity?

Strong thesis

Health care in one line

The U.S. leaks through commercial fragmentation and administrative choke points. China leaks less through price and coverage structure, but still wrestles with institutional tensions inside a more state-directed system.